Cimzia® (certolizumab pegol)
demonstrates sustained
remission at a reduced
maintenance dose in
severe active axSpA.2
The first anti-TNF with a licensed indication for
reduced maintenance dosing in severe active axSpA.1-8
Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis1
Click here to visit emc for the full indication details (SmPC)
Due to the emerging biosimilar market, trusts are being encouraged to use the best value biologic as the first line option.9 In addition to financial costs, it is important to consider the wider impact on the patient, their family and the NHS when a patient is on a treatment journey e.g. switching treatments, repeated hospital visits, loss of work days.10
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.
Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.
Help us to grow our resource the way you want it to grow.